Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05013606 · ClinicalTrials.gov registry record · NA
Hydrogen Water Treatment for Chronic Fatigue Syndrome
A NA study, sponsored by Stony Brook University.
- Completed
- Registry status
- NA
- Development phase
- 23
- Enrollment target
NCT05013606 is a NA study that has completed, run by Stony Brook University. The registered enrollment target is 23 participants.
The verdict
NCT05013606, a NA study, has completed, sponsored by Stony Brook University.
- COMPLETED
- Registry status
- NA
- Development phase
- 23 participants
- Enrollment target
Study Summary
The proposed placebo-controlled pilot study will examine hydrogen water as a treatment for myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). 25 subjects who meet strict criteria for ME/CFS will be recruited. The 30 day trial will involve subjects ingesting 1-5 8 oz. glasses of hydrogen-dissolved water per day. The placebo condition will involve the same daily ingestion schedule but with an inert placebo pill instead of the active hydrogen treatment pill. The proposed study is intended to establish feasibility of the clinical protocol and examine potential treatment effects of hydrogen water which may include symptom reduction and possibly improved functioning. If feasibility and apparent treatment effects are confirmed, a large clinical trial will be proposed for submission to NIH. In addition to potential therapeutic properties, H2 water is portable, easily administered and safe to ingest. Self-report assessments for ME/CFS symptoms, fatigue, autonomic symptoms, physical function, anxiety, and depression will be done in the week before and the week after the 30 day trial. In addition, 7-day home-based objective assessments of heart rate variability (a measure of parasympathetic function) and accelerometry (a physical activity assessment) will be scheduled before and after the intervention period.
Interventions
- DIETARY_SUPPLEMENT Hydrogen water
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2019-04-01 |
| Est. Completion | 2021-06-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05013606
The ClinicalTrials.gov registry entry for NCT05013606 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stony Brook University, which has 127 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Hydrogen water is the first listed.
NCT05013606 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05013606 about?
NCT05013606 is a clinical study titled "Hydrogen Water Treatment for Chronic Fatigue Syndrome". The proposed placebo-controlled pilot study will examine hydrogen water as a treatment for myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). 25 subjects who meet strict criteria for ME/CFS will be recruited. The 30 day trial will involve subjects ingesting 1-5 8 oz. glasses of hydrogen-di...
What is the current status of trial NCT05013606?
This trial is currently completed. It is a NA study. The enrollment target is 23 participants. The study started on 2019-04-01. Estimated completion is 2021-06-01.
What interventions are being tested in trial NCT05013606?
The interventions under investigation include: Hydrogen water (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT05013606?
This trial is sponsored by Stony Brook University, which has 127 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.